Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop

Albert C. Ludolph, Caterina Bendotti, Eran Blaugrund, Bastian Hengerer, Jean Philippe Löffler, Joanne Martin, Vincent Meininger, Thomas Meyer, Saliha Moussaoui, Wim Robberecht, Sean Scott, Vincenzo Silani, Leonard H. Van Den Berg

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

A transgenic animal model for anterior horn cell loss was established in 1994. This model is based on the insertion of a high copy number of disease-causing human Cu/Zn SOD mutations into the intact mouse genome. It serves to establish hypotheses for the pathogenesis of anterior horn cell death, but also to test potential pharmacological approaches to therapy in human ALS. Today, more than 100 - published and unpublished - compounds have been tested in this animal model, a large part of them being reported as successful. However, it proved to be difficult to translate these therapeutic successes in the animal model into human trials. Also, a number of disease-modifying strategies were difficult to reproduce, even by the same group. On the other hand, the step from mice to men means a huge investment for the sponsors of clinical trials and the scientific community. Therefore, establishment of standard methods for drug testing in ALS models is mandatory. In this workshop, clinical and preclinical researchers established in the field of ALS/MND met in Holland in March 2006 in order to establish guidelines for the community for drug testing in mouse models.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalAmyotrophic Lateral Sclerosis
Volume8
Issue number4
DOIs
Publication statusPublished - 2007

Fingerprint

Anterior Horn Cells
Animal Models
Pharmacology
Guidelines
Education
Pharmaceutical Preparations
Genetically Modified Animals
Netherlands
Cell Death
Research Personnel
Clinical Trials
Genome
Mutation
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND : Report on the 142nd ENMC international workshop. / Ludolph, Albert C.; Bendotti, Caterina; Blaugrund, Eran; Hengerer, Bastian; Löffler, Jean Philippe; Martin, Joanne; Meininger, Vincent; Meyer, Thomas; Moussaoui, Saliha; Robberecht, Wim; Scott, Sean; Silani, Vincenzo; Van Den Berg, Leonard H.

In: Amyotrophic Lateral Sclerosis, Vol. 8, No. 4, 2007, p. 217-223.

Research output: Contribution to journalArticle

Ludolph, AC, Bendotti, C, Blaugrund, E, Hengerer, B, Löffler, JP, Martin, J, Meininger, V, Meyer, T, Moussaoui, S, Robberecht, W, Scott, S, Silani, V & Van Den Berg, LH 2007, 'Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop', Amyotrophic Lateral Sclerosis, vol. 8, no. 4, pp. 217-223. https://doi.org/10.1080/17482960701292837
Ludolph, Albert C. ; Bendotti, Caterina ; Blaugrund, Eran ; Hengerer, Bastian ; Löffler, Jean Philippe ; Martin, Joanne ; Meininger, Vincent ; Meyer, Thomas ; Moussaoui, Saliha ; Robberecht, Wim ; Scott, Sean ; Silani, Vincenzo ; Van Den Berg, Leonard H. / Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND : Report on the 142nd ENMC international workshop. In: Amyotrophic Lateral Sclerosis. 2007 ; Vol. 8, No. 4. pp. 217-223.
@article{4285a97518b340119cb833ef7083c3f6,
title = "Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop",
abstract = "A transgenic animal model for anterior horn cell loss was established in 1994. This model is based on the insertion of a high copy number of disease-causing human Cu/Zn SOD mutations into the intact mouse genome. It serves to establish hypotheses for the pathogenesis of anterior horn cell death, but also to test potential pharmacological approaches to therapy in human ALS. Today, more than 100 - published and unpublished - compounds have been tested in this animal model, a large part of them being reported as successful. However, it proved to be difficult to translate these therapeutic successes in the animal model into human trials. Also, a number of disease-modifying strategies were difficult to reproduce, even by the same group. On the other hand, the step from mice to men means a huge investment for the sponsors of clinical trials and the scientific community. Therefore, establishment of standard methods for drug testing in ALS models is mandatory. In this workshop, clinical and preclinical researchers established in the field of ALS/MND met in Holland in March 2006 in order to establish guidelines for the community for drug testing in mouse models.",
author = "Ludolph, {Albert C.} and Caterina Bendotti and Eran Blaugrund and Bastian Hengerer and L{\"o}ffler, {Jean Philippe} and Joanne Martin and Vincent Meininger and Thomas Meyer and Saliha Moussaoui and Wim Robberecht and Sean Scott and Vincenzo Silani and {Van Den Berg}, {Leonard H.}",
year = "2007",
doi = "10.1080/17482960701292837",
language = "English",
volume = "8",
pages = "217--223",
journal = "Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders",
issn = "1466-0822",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND

T2 - Report on the 142nd ENMC international workshop

AU - Ludolph, Albert C.

AU - Bendotti, Caterina

AU - Blaugrund, Eran

AU - Hengerer, Bastian

AU - Löffler, Jean Philippe

AU - Martin, Joanne

AU - Meininger, Vincent

AU - Meyer, Thomas

AU - Moussaoui, Saliha

AU - Robberecht, Wim

AU - Scott, Sean

AU - Silani, Vincenzo

AU - Van Den Berg, Leonard H.

PY - 2007

Y1 - 2007

N2 - A transgenic animal model for anterior horn cell loss was established in 1994. This model is based on the insertion of a high copy number of disease-causing human Cu/Zn SOD mutations into the intact mouse genome. It serves to establish hypotheses for the pathogenesis of anterior horn cell death, but also to test potential pharmacological approaches to therapy in human ALS. Today, more than 100 - published and unpublished - compounds have been tested in this animal model, a large part of them being reported as successful. However, it proved to be difficult to translate these therapeutic successes in the animal model into human trials. Also, a number of disease-modifying strategies were difficult to reproduce, even by the same group. On the other hand, the step from mice to men means a huge investment for the sponsors of clinical trials and the scientific community. Therefore, establishment of standard methods for drug testing in ALS models is mandatory. In this workshop, clinical and preclinical researchers established in the field of ALS/MND met in Holland in March 2006 in order to establish guidelines for the community for drug testing in mouse models.

AB - A transgenic animal model for anterior horn cell loss was established in 1994. This model is based on the insertion of a high copy number of disease-causing human Cu/Zn SOD mutations into the intact mouse genome. It serves to establish hypotheses for the pathogenesis of anterior horn cell death, but also to test potential pharmacological approaches to therapy in human ALS. Today, more than 100 - published and unpublished - compounds have been tested in this animal model, a large part of them being reported as successful. However, it proved to be difficult to translate these therapeutic successes in the animal model into human trials. Also, a number of disease-modifying strategies were difficult to reproduce, even by the same group. On the other hand, the step from mice to men means a huge investment for the sponsors of clinical trials and the scientific community. Therefore, establishment of standard methods for drug testing in ALS models is mandatory. In this workshop, clinical and preclinical researchers established in the field of ALS/MND met in Holland in March 2006 in order to establish guidelines for the community for drug testing in mouse models.

UR - http://www.scopus.com/inward/record.url?scp=34547587021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547587021&partnerID=8YFLogxK

U2 - 10.1080/17482960701292837

DO - 10.1080/17482960701292837

M3 - Article

C2 - 17653919

AN - SCOPUS:34547587021

VL - 8

SP - 217

EP - 223

JO - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

JF - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

SN - 1466-0822

IS - 4

ER -